WO2018097603A3 - Composition immunogène de protéine s du coronavirus du syndrome respiratoire du moyen-orient et son procédé de préparation - Google Patents

Composition immunogène de protéine s du coronavirus du syndrome respiratoire du moyen-orient et son procédé de préparation Download PDF

Info

Publication number
WO2018097603A3
WO2018097603A3 PCT/KR2017/013365 KR2017013365W WO2018097603A3 WO 2018097603 A3 WO2018097603 A3 WO 2018097603A3 KR 2017013365 W KR2017013365 W KR 2017013365W WO 2018097603 A3 WO2018097603 A3 WO 2018097603A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic composition
respiratory syndrome
preparing same
middle east
syndrome coronavirus
Prior art date
Application number
PCT/KR2017/013365
Other languages
English (en)
Korean (ko)
Other versions
WO2018097603A2 (fr
Inventor
김학
함동수
권태우
김창신
김훈
서기원
Original Assignee
에스케이바이오사이언스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오사이언스 주식회사 filed Critical 에스케이바이오사이언스 주식회사
Publication of WO2018097603A2 publication Critical patent/WO2018097603A2/fr
Publication of WO2018097603A3 publication Critical patent/WO2018097603A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition immunogène de protéine S du coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV S) comprenant au moins un polypeptide choisi dans un groupe constitué par les SEQ ID No : 2, 4, 6 et 8, et son procédé de préparation. La composition immunogène préparée par le procédé de la présente invention est susceptible d'être obtenue avec un rendement élevé et peut fournir une composition permettant une meilleure prévention du MERS-CoV.
PCT/KR2017/013365 2016-11-23 2017-11-22 Composition immunogène de protéine s du coronavirus du syndrome respiratoire du moyen-orient et son procédé de préparation WO2018097603A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0156610 2016-11-23
KR20160156610 2016-11-23

Publications (2)

Publication Number Publication Date
WO2018097603A2 WO2018097603A2 (fr) 2018-05-31
WO2018097603A3 true WO2018097603A3 (fr) 2019-01-24

Family

ID=62195284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013365 WO2018097603A2 (fr) 2016-11-23 2017-11-22 Composition immunogène de protéine s du coronavirus du syndrome respiratoire du moyen-orient et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR20180058206A (fr)
WO (1) WO2018097603A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102601258B1 (ko) * 2020-02-25 2023-11-13 (주)지뉴인텍 코로나바이러스감염증-19(covid-19)에 대한 재조합 아데노바이러스 백신 및 이를 이용한 병용요법
US20210268101A1 (en) * 2020-03-02 2021-09-02 Cel-Sci Corporation NOVEL PEPTIDES FOR VACCINATION AND TREATMENT OF 2019-nCoV INFECTIONS
WO2021215857A1 (fr) * 2020-04-22 2021-10-28 포항공과대학교 산학협력단 Protéine spike recombinante de la maladie du coronavirus 2019 (covid-19) formant un trimère, procédé de production de masse de protéine spike recombinante dans des plantes et procédé de préparation de composition de vaccin à base de celle-ci
US20230355745A1 (en) * 2020-09-07 2023-11-09 Gi Cell, Inc. Coronavirus-derived receptor-binding domain variant having reduced ace2-binding affinity and vaccine composition comprising the same
KR20230158245A (ko) 2022-05-11 2023-11-20 국방과학연구소 Covid-19 유전자 백신용 dna 단편 및 이를 포함한 유전자 백신용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015081155A1 (fr) * 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Vaccin à base de mers-cov
US20150337029A1 (en) * 2014-05-23 2015-11-26 Regeneron Pharmaceuticals, Inc. Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
KR20160055164A (ko) * 2013-09-19 2016-05-17 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
US20160264647A1 (en) * 2013-10-18 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
US20160296617A1 (en) * 2013-03-01 2016-10-13 New York Blood Center, Inc. Immunogenic Composition for MERS Coronavirus Infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160296617A1 (en) * 2013-03-01 2016-10-13 New York Blood Center, Inc. Immunogenic Composition for MERS Coronavirus Infection
KR20160055164A (ko) * 2013-09-19 2016-05-17 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
US20160264647A1 (en) * 2013-10-18 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides
WO2015081155A1 (fr) * 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Vaccin à base de mers-cov
US20150337029A1 (en) * 2014-05-23 2015-11-26 Regeneron Pharmaceuticals, Inc. Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein

Also Published As

Publication number Publication date
KR20180058206A (ko) 2018-05-31
WO2018097603A2 (fr) 2018-05-31

Similar Documents

Publication Publication Date Title
WO2018097603A3 (fr) Composition immunogène de protéine s du coronavirus du syndrome respiratoire du moyen-orient et son procédé de préparation
MX2019008037A (es) Aislados de bacillus y usos de los mismos.
EP3708660A3 (fr) Polypeptides
MY193249A (en) Anti-human cd19 antibodies with high affinity
WO2017070626A3 (fr) Vaccins contre les virus respiratoires
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
WO2018004308A3 (fr) Nouvelle fructose-6-phosphate-3-épimérase résistante à la chaleur et procédé de production d'allulose à l'aide de celle-ci
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
WO2015191693A3 (fr) Procédé d'édition génique
MX2021006697A (es) Composición y método para el crecimiento del cabello.
PH12019500989A1 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
WO2017214596A8 (fr) Compositions et procédés pour prévenir et traiter l'infection par le virus zika
MX2017008563A (es) Novedoso bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga y su uso para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga.
EP3778901A4 (fr) Nouveau promoteur et procédé de production de l'acide l-aminé mettant en oeuvre ledit promoteur
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
WO2015107363A3 (fr) Composition d'antigène mycobactérien
MX2020008125A (es) Composiciones que comprenden berberina.
WO2017011340A3 (fr) Protéines et compositions immunisantes contenant des protéines de klebsiella et leurs procédés d'utilisation
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
EP4327880A3 (fr) Forme à l'état solide de succinate de ribociclib
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
MY187334A (en) Xylanase
PH12021550441A1 (en) Modified pedv spike protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17873251

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17873251

Country of ref document: EP

Kind code of ref document: A2